Aarti Industries Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/x3bvj68qbs9j008v8rfarq0m.pdf

Key Takeaways


The Dyes & Pigments Downturn

Rajendra Gogri: "I think the dyes and pigments segments are weak. So, I think that will continue in the second half also. That is the main reason for lower guidance. Hopefully the things start recovering in Q4 and the next year, we don't have any impact of this slowdown in this segment."

The Growth Engine: Long-Term Contracts & Capex

Rajendra Gogri: "We have a long-term visibility of the products. So as such, we are not looking at any slowdown in the CapEx."

Operating Leverage & Margin Mechanics

Rajendra Gogri: "In the next two years, we expect direct transfer of gross profit to EBITDA because we don't expect much of fixed costs or employee cost increase in the next couple of years, other than the normal increments. So that's why we are targeting a 25% CAGR."

Nitric Acid: A Strategy Still Taking Shape

Rajendra Gogri: "The comprehensive nitric strategy is what we were planning to share in this call but it may take some more time and we'll come out with the comprehensive strategy."

Financials: A Quarter of Headwinds


Guidance & Commitments

CommitmentSpecificsTimeline
FY23 EBITDATarget around ₹1,100 croreFY23
FY24 & FY25 EBITDA CAGR25% CAGR, targeting ₹1,700 crore by FY25FY24-FY25
Collective capexAround ₹3,000 croreFY24 and FY25
Third long-term contract commissioningConstruction progressing wellEnd of Q3 FY23
First long-term contract utilisationRamp to ~70% utilisationNext financial year (FY24)
CWIP capitalisation~₹1,000 crore to be capitalisedH2 FY23
Ethylation capacity commissioningTriple capacity at Dahej SEZ, ~₹200 crore investmentH1 FY25
Concentrated nitric acid plant commissioningOrder placedQ4 FY24
Dyes & pigments normalizationBoth segments to contribute normally to volumesBy FY25
Pharma demerger listingAarti Pharmalabs Limited listingDecember 2022
New initiatives commissioningChloro Toluene, multipurpose plants, etc.H2 FY25 into FY26
Comprehensive FY27 guidanceTo be providedNext couple of quarters

Key Metrics

MetricQ2 FY23
Revenue₹1,847 cr, +29% YoY; exports contributed over 50% of total revenues
EBITDA₹267 cr, +5% YoY; +30% YoY after normalising for ₹52 cr shortfall fees in Q2 FY22
Profit after tax₹124 cr
Negative FOREX mark-to-market impact₹20 cr, impacting PAT
FY23 EBITDA guidance~₹1,100 cr
EBITDA CAGR guidance for FY24 & FY25~25%
FY25 EBITDA target~₹1,700 cr, based on 25% CAGR from FY23
Value-added products share78% of sales
Nitrochlorobenzene production20,276 MT
Nitro-Toluene production4,954 MT
PDA volumes~242 tons per month
Dicamba intermediate utilisation~25% (720 tonnes per quarter vs. 2,400 tonnes capacity); currently not breakeven
Ethylation capacity utilisation (Dahej SEZ)~90%
H1 FY23 CAPEX₹577 cr
FY23 CAPEX target~₹1,100 to 1,200 cr
Collective CAPEX for FY24 and FY25~₹3,000 cr
Maintenance shutdown impact on profitability~₹15 cr
Currency benefit in Q2~₹8 cr to ₹10 cr
R&D pipeline50+ products in Chemicals at various stages